These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 9826581

  • 1. Role of 4-1BB in immune responses.
    Vinay DS, Kwon BS.
    Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
    [Abstract] [Full Text] [Related]

  • 2. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
    Cho HR, Kwon B, Yagita H, La S, Lee EA, Kim JE, Akiba H, Kim J, Suh JH, Vinay DS, Ju SA, Kim BS, Mittler RS, Okumura K, Kwon BS.
    Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
    [Abstract] [Full Text] [Related]

  • 3. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
    Cheuk AT, Mufti GJ, Guinn BA.
    Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
    [Abstract] [Full Text] [Related]

  • 4. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
    DeBenedette MA, Shahinian A, Mak TW, Watts TH.
    J Immunol; 1997 Jan 15; 158(2):551-9. PubMed ID: 8992967
    [Abstract] [Full Text] [Related]

  • 5. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S.
    Cancer Res; 2001 Mar 01; 61(5):2031-7. PubMed ID: 11280763
    [Abstract] [Full Text] [Related]

  • 6. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
    Hurtado JC, Kim YJ, Kwon BS.
    J Immunol; 1997 Mar 15; 158(6):2600-9. PubMed ID: 9058792
    [Abstract] [Full Text] [Related]

  • 7. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
    Martinet O, Divino CM, Zang Y, Gan Y, Mandeli J, Thung S, Pan PY, Chen SH.
    Gene Ther; 2002 Jun 15; 9(12):786-92. PubMed ID: 12040460
    [Abstract] [Full Text] [Related]

  • 8. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.
    Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS.
    J Immunol; 1995 Oct 01; 155(7):3360-7. PubMed ID: 7561030
    [Abstract] [Full Text] [Related]

  • 9. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.
    Choi BK, Bae JS, Choi EM, Kang WJ, Sakaguchi S, Vinay DS, Kwon BS.
    J Leukoc Biol; 2004 May 01; 75(5):785-91. PubMed ID: 14694186
    [Abstract] [Full Text] [Related]

  • 10. Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB.
    Cannons JL, Hoeflich KP, Woodgett JR, Watts TH.
    J Immunol; 1999 Sep 15; 163(6):2990-8. PubMed ID: 10477561
    [Abstract] [Full Text] [Related]

  • 11. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses.
    Tan JT, Ha J, Cho HR, Tucker-Burden C, Hendrix RC, Mittler RS, Pearson TC, Larsen CP.
    Transplantation; 2000 Jul 15; 70(1):175-83. PubMed ID: 10919597
    [Abstract] [Full Text] [Related]

  • 12. Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.
    Sica G, Chen L.
    Arch Immunol Ther Exp (Warsz); 1999 Jul 15; 47(5):275-9. PubMed ID: 10604232
    [Abstract] [Full Text] [Related]

  • 13. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
    Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP.
    J Immunol; 1999 Nov 01; 163(9):4859-68. PubMed ID: 10528187
    [Abstract] [Full Text] [Related]

  • 14. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE.
    Cancer Res; 2003 May 15; 63(10):2546-52. PubMed ID: 12750278
    [Abstract] [Full Text] [Related]

  • 15. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
    Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB.
    Immunology; 2004 Aug 15; 112(4):559-66. PubMed ID: 15270726
    [Abstract] [Full Text] [Related]

  • 16. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
    Lee J, Lee EN, Kim EY, Lee HJ, Park HJ, Sun CL, Lee SK, Joh JW, Lee KW, Kwon GY, Kim SJ.
    Transplant Proc; 2005 Aug 15; 37(1):123-5. PubMed ID: 15808569
    [Abstract] [Full Text] [Related]

  • 17. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF, Chen L, Zheng P, Liu Y.
    Cancer Res; 2002 Jun 15; 62(12):3459-65. PubMed ID: 12067989
    [Abstract] [Full Text] [Related]

  • 18. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
    Vinay DS, Kwon BS.
    Cell Immunol; 1999 Feb 25; 192(1):63-71. PubMed ID: 10066348
    [Abstract] [Full Text] [Related]

  • 19. Genomic organization and chromosomal localization of the T-cell antigen 4-1BB.
    Kwon BS, Kozak CA, Kim KK, Pickard RT.
    J Immunol; 1994 Mar 01; 152(5):2256-62. PubMed ID: 8133039
    [Abstract] [Full Text] [Related]

  • 20. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B.
    Jang IK, Lee ZH, Kim YJ, Kim SH, Kwon BS.
    Biochem Biophys Res Commun; 1998 Jan 26; 242(3):613-20. PubMed ID: 9464265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.